News - Pharmaphorum

EU regulators also backed Trelegy

COPD triple approved, can GSK maximise its revenues?

https://pharmaphorum.com/news/gsk-launch-copd-triple-therapy-us/

Teva sells women’s health division to tackle $35bn debts

Teva has sold its women’s health business in order to pay off some of its $35 billion in

Teva sells women’s health division to tackle $35bn debts

https://pharmaphorum.com/news/teva-sells-womens-health-business-bid-tackle-debts/

EU regulators reject Santhera’s Raxone for DMD

Swiss company to appeal regulators’ decision.

EU regulators reject Santhera’s Raxone for DMD

https://pharmaphorum.com/news/eu-regulators-reject-santheras-raxone-dmd/

See all

This week’s news

Brain controlled app helps children with ADHD

App significantly improves behaviour and attention in children with ADHD.

Brain controlled app helps children with ADHD

https://pharmaphorum.com/news/brain-controlled-app-adhd/

Tesaro’s Zejula primed for EU approval, battle with AZ

EU regulators recommend PARP inhibitor Zejula

Tesaro’s Zejula primed for EU approval, battle with AZ

https://pharmaphorum.com/news/tesaro/

Roche cancer blockbusters face competition in US and EU

Bayer has gained FDA accelerated approval for its follicular lymphoma drug Aliqopa (copanlisib), giving it entry to the

Roche cancer blockbusters face competition in US and EU

https://pharmaphorum.com/news/roche-cancer-drugs-facing-competition-us-eu/

Latest NHS digital ‘fast followers’ named

September 15, 2017

Eighteen ‘fast follower’ NHS trusts will be paired with NHS Global Digital Exemplars.

Latest NHS digital ‘fast followers’ named

https://pharmaphorum.com/news/digital-pioneer-fast-follower-nhs/

Novo highlights key ‘hypo’ data from Tresiba at EASD

September 15, 2017

Novo hopes data will justify higher price compared with rival.

Novo highlights key ‘hypo’ data from Tresiba at EASD

https://pharmaphorum.com/news/novo-highlights-key-hypo-data-easd/

Bayer gains first Aliqopa approval in follicular lymphoma

September 15, 2017

Bayer gains first Aliqopa approval in follicular lymphoma

https://pharmaphorum.com/news/aliqopa-follicular-lymphoma/

AZ talks up Bydureon data, GLP-1 and glucagon combo

AstraZeneca is hoping new data showing its Bydureon diabetes drug cuts overall death risk could stave off competition

AZ talks up Bydureon data, GLP-1 and glucagon combo

https://pharmaphorum.com/news/az-hopes-bydureon-mortality-benefit-stave-off-threat-novo/

BMS and Roche look to Halozyme drug delivery for IO advantage

Bristol-Myers Squibb is to work with drug delivery specialist Halozyme to create an injectable form of its blockbuster

BMS and Roche look to Halozyme drug delivery for IO advantage

https://pharmaphorum.com/news/bms-roche-look-halozyme-drug-delivery-io-advantage/

More data supports Jardiance lead in cardiovascular battle

Cardioprotective effect occurred in patients independently of blood sugar control

More data supports Jardiance lead in cardiovascular battle

https://pharmaphorum.com/news/bililly-produce-data-supporting-diabetes-drug-jardiance/

Merck funds Antidote’s clinical trial matching tech

Funding will go toward expansion of platform capabilities.

Merck funds Antidote’s clinical trial matching tech

https://pharmaphorum.com/news/merck-clinical-trial-matching-antidote/

Tipped to hit $1bn, GSK’s Shingrix gains committee approval

GlaxoSmithKline’s shingles vaccine Shingrix has gained the unanimous backing of an FDA advisory committee. The Vaccines and Related

Tipped to hit $1bn, GSK’s Shingrix gains committee approval

https://pharmaphorum.com/news/tipped-hit-1bn-gsks-shingrix-gains-committee-approval/

New Apple Watch to feature enhanced heart health tracking

Heart Rate app will feature in FDA and Stanford study.

New Apple Watch to feature enhanced heart health tracking

https://pharmaphorum.com/news/apple-watch-heart-health/

FDA’s Gottlieb vows to close orphan drug loopholes

FDA commissioner Scott Gottlieb is continuing his plans to streamline and accelerate the regulators’ practices, but now plans

FDA’s Gottlieb vows to close orphan drug loopholes

https://pharmaphorum.com/news/fdas-gottlieb-vows-close-orphan-drug-loopholes/

Janssen axes hep C development with Achillion

Johnson & Johnson has ended a collaboration with US biotech Achillion to develop hepatitis C drugs, sending the

Janssen axes hep C development with Achillion

https://pharmaphorum.com/news/jj-axes-hepatitis-c-drug-rd-deal-achillion/

Novo showcases next-gen GLP-1 at EASD

Semaglutide is under review in Europe and US.

Novo showcases next-gen GLP-1 at EASD

https://pharmaphorum.com/news/novo-showcases-next-gen-glp-1-easd/

Partner content

Press releases

Have you seen the agenda for Social Media in Pharma?

Have you seen the agenda for Social Media in Pharma?

https://pharmaphorum.com/partner-content/have-you-seen-the-agenda-for-social-media-in-pharma/

5 Key Reasons Why You Should Attend Europe’s Leading Ophthalmic Conference

5 Key Reasons Why You Should Attend Europe’s Leading Ophthalmic Conference

https://pharmaphorum.com/partner-content/5-key-reasons-why-you-should-attend-europes-leading-ophthalmic-conference/

Updates in Cutting Edge Lyophilization Technology